Guggenheim raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $90 from $60 and keeps a Buy rating on the shares after the company announced topline results from the Phase 3 X-TOLE2 study evaluating azetukalner in adults with focal onset seizures. The firm, which now estimates $2.3B in global peak sales, notes that Xenon plans to submit its NDA in Q3 of 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Xenon Pharmaceuticals price target raised to $68 from $49 at Wells Fargo
- Biohaven price target raised to $27 from $24 at Goldman Sachs
- Xenon Pharmaceuticals price target raised to $75 from $52 at Goldman Sachs
- Xenon Pharmaceuticals price target raised to $74 from $53 at H.C. Wainwright
- Xenon Pharmaceuticals price target raised to $90 from $56 at Deutsche Bank